You just read:

Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

News provided by

QIAGEN

Jun 03, 2017, 13:00 ET